“Pfizer believes the supply of generic pregabalin for use in the treatment of pain whilst the pain patent remains in force in the U.K. would infringe Pfizer’s patent rights,” the letter states, going on to urge addressees to make sure prescribers know about the pain patent and advise clinicians to prescribe Lyrica by brand when using the drug to treat neuropathic pain.
It’s not just friendly advice. The letter closes with a not-so-veiled threat of legal action. “[I]nstructing or encouraging the usage of generic pregabalin in pain would amount to procurement of patent infringement (an unlawful act),” the letter states. “Pfizer therefore reserves all of its legal rights in this regard.”